Clinical Trial Update: Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ga-68 DOTATATE PET/CT for diagnosing metastatic castration-resistant prostate cancer has completed, with results posted July 17, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ga-68 DOTATATE PET/CT (gallium-68 DOTATATE)

Snippet

Sponsor: Emory University | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-17